630 related articles for article (PubMed ID: 19152429)
1. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
[TBL] [Abstract][Full Text] [Related]
2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
7. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
Cazzola M
Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
9. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
[TBL] [Abstract][Full Text] [Related]
11. Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia.
Bowen D; Hyslop A; Keenan N; Groves M; Culligan D; Johnson P; Shaw A; Geddes F; Evans P; Porter J; Cavill I
Haematologica; 2006 May; 91(5):709-10. PubMed ID: 16670077
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P
Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349
[TBL] [Abstract][Full Text] [Related]
13. Treatment of myelodysplastic syndromes with hematopoietic growth factors.
Ganser A; Hoelzer D
Hematol Oncol Clin North Am; 1992 Jun; 6(3):633-53. PubMed ID: 1377194
[TBL] [Abstract][Full Text] [Related]
14. [The use of erythropoietin alpha in programs of high-dose chemotherapy].
Danova M; Aglietta M; Pierelli L; Ferrari S; Perillo A; Scambia G; Henry D
Recenti Prog Med; 2000 Dec; 91(12):681-9. PubMed ID: 11194490
[TBL] [Abstract][Full Text] [Related]
15. Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes.
Casadevall N
Semin Oncol; 1998 Jun; 25(3 Suppl 7):12-8. PubMed ID: 9671324
[TBL] [Abstract][Full Text] [Related]
16. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S
Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669
[TBL] [Abstract][Full Text] [Related]
17. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
18. [Clinical use of granulocyte colony stimulating-factors (GM-CSF and G-CSF].
Borota R; Borota J; Belić A; Gebauer E; Stefanović N
Med Pregl; 1997; 50(3-4):87-93. PubMed ID: 9229690
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic protection by dexamethasone or granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients treated with carboplatin and ifosfamide.
Rinehart J; Keville L; Neidhart J; Wong L; DiNunno L; Kinney P; Aberle M; Tadlock L; Cloud G
Am J Clin Oncol; 2003 Oct; 26(5):448-58. PubMed ID: 14528069
[TBL] [Abstract][Full Text] [Related]
20. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.
Balleari E; Clavio M; Arboscello E; Bellodi A; Bruzzone A; Del Corso L; Lucchetti MV; Miglino M; Passalia C; Pierri I; Ponassi I; Oneto C; Racchi O; Scudeletti M; Vignolo L; Zoppoli G; Gobbi M; Ghio R
Leuk Res; 2011 Nov; 35(11):1472-6. PubMed ID: 21794914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]